Guidant ICD, Stent Tactics Assuage Wall Street; Q1 Index Inches Up

Guidant allayed investor uncertainty over its future business strategy by winning a favorable MCAC reimbursement recommendation and executing a string of stent technology acquisitions, propelling the stock ahead 17.3% for the first quarter